Press Releases :: OPKO Health, Inc. (OPK)

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Read the news release

Visit BioReference Health

Year

Category

Feb 17, 2022 8:00 am EST

OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022

Feb 15, 2022 11:30 am EST

Pfizer and OPKO’s Once-Weekly NGENLATM (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency

Feb 3, 2022 8:30 am EST

RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP

Jan 21, 2022 8:00 am EST

Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency

Jan 20, 2022 8:00 am EST

JAPAN’S MHLW APPROVES PFIZER AND OPKO’S NGENLA® (SOMATROGON), A NEW LONG-ACTING TREATMENT FOR PEDIATRIC GROWTH HORMONE DEFICIENCY

Jan 18, 2022 11:51 am EST

Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

Jan 5, 2022 4:05 pm EST

OPKO Health to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Dec 23, 2021 8:00 am EST

OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients

Dec 8, 2021 8:00 am EST

OPKO Health Receives U.S. FDA Approval for the 4Kscore® Test

Dec 6, 2021 8:00 am EST

OPKO Health Announces the Passing of Director Dr. Richard Lerner